Skip to main content

Table 1 Patient characteristics

From: Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Characteristic L-AmB (n = 60) CAS (n = 60)
No. of patients (%)
Gender   
 male 33 (55.0) 38 (63.3)
 female 27 (45.0) 22 (36.7)
Age group   
 < 6 yr. 20 (33.3) 17 (28.3)
 6 - 11 yr. 24 (40.0) 20 (33.3)
 12 - < 18 yr. 16 (26.7) 23 (38.3)
Donor   
 MUD 20 (33.3) 19 (31.7)
 MMUD 4 (6.7) 1 (1.7)
 MMFD 29 (48.3) 23 (38.3)
 MFD 7 (11.7) 17 (28.3)
Primary diagnosis   
 ALL 18 (30.0) 17 (28.3)
 AML 7 (11.7) 1 (1.7)
 JMML 3 (5.0) 2 (3.3)
 CML 3 (5.0) -
 MDS 6 (10.0) 5 (8.3)
 NHL 1 (1.7) 3 (5.0)
 Solid tumors 9 (15.0) 10 (16.7)
 Aplastic anemia 1 (1.7) 10 (16.7)
 Neurometabolic diseases 5 (8.3) 5 (8.3)
 Immunodeficiency 4 (6.7) 7 (11.7)
 Chediak-Higashi-syndrome 2 (3.3) -
 Morbus Kostmann 1 (1.7) -
Graft-versus-Host Disease   
 Grade I 22 (36.7) 24 (40.0)
 Grade II 4 (6.7) 5 (8.3)
 Grade III 2 (3.3) 2 (3.3)
 Grade IV 2 (3.3) 2 (3.3)
 Chronic limited 1 (1.7) 3 (5.3)
 Chronic extensive 1 (1.7) 1 (1.7)
  1. Abbreviation: ALL, acute lymphoblastic leukemia; AML acute myelogenous leukemia; CAS, caspofungin; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia; L-AmB, liposomal amphotericin B; MDS, myelodysplastic syndromes; MFD, matched family donor; MMFD, mismatched family donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; NHL, Non-Hodgkin lymphoma.